Subscribe To

Price Alert Latest News Economic Calendar News

MDWD / MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers

MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs). The study randomized 120 patients, of which 119 patients were treated by either EscharEx (n=46), a gel vehicle (n=43), or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement (n=30). Read More

Demo Live Account See Partner Details

Content Topics

Mediwound

Escharex

Mid

Stage

Trial

Meets

Primary

Goal

Mediwound s

Mid stage

Venous

Ulcers

Stock

MDWD

Posted: Jan 24 2022, 07:13

Author Name: Benzinga

MDWD News

By Zacks Investment Research
September 29, 2023

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisio

By GlobeNewsWire
September 5, 2023

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generati

By Zacks Investment Research
August 15, 2023

MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates

MediWound (MDWD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.41 per share. This compares

By Seeking Alpha
May 31, 2023

MediWound: With Expenses Covered, Growth Is Within Reach

MediWound, a company developing medical solutions for skin and burn conditions, is set to begin US distribution of its burn solution NexoBrid in Q3 20

By Zacks Investment Research
May 30, 2023

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound (MDWD) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0

By Seeking Alpha
March 16, 2023

MediWound Ltd. (MDWD) Q4 2022 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofe

By Zacks Investment Research
March 16, 2023

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers ho

By GlobeNewsWire
March 2, 2023

MediWound to Report Fourth Quarter and Year-End 2022 Financial Results

Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 16 at 8

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.